Merck & Co (MRK)

Add to Watchlists
Create an Alert
57.63 +0.70  +1.23% NYSE Jul 1, 5:00PM Delayed 2m USD

Merck & Co Research and Development Expense (Quarterly):

1.737B for March 31, 2015

View 4,000+ financial data types

View Full Chart

Merck & Co Research and Development Expense (Quarterly) Chart

Export Data
Save Image

Merck & Co Historical Research and Development Expense (Quarterly) Data

View and export this data going back to 1984. Start your Free Trial
Export Data Date Range:
Data for this Date Range  
March 31, 2015 1.737B
Dec. 31, 2014 2.283B
Sept. 30, 2014 1.659B
June 30, 2014 1.664B
March 31, 2014 1.574B
Dec. 31, 2013 1.835B
Sept. 30, 2013 1.66B
June 30, 2013 2.101B
March 31, 2013 1.907B
Dec. 31, 2012 2.224B
Sept. 30, 2012 1.918B
June 30, 2012 2.165B
March 31, 2012 1.862B
Dec. 31, 2011 2.419B
Sept. 30, 2011 1.954B
June 30, 2011 1.936B
March 31, 2011 2.158B
Dec. 31, 2010 4.559B
Sept. 30, 2010 2.322B
June 30, 2010 2.179B
March 31, 2010 2.051B
Dec. 31, 2009 1.972B
Sept. 30, 2009 1.254B
June 30, 2009 1.395B
March 31, 2009 1.224B
Dec. 31, 2008 1.387B
Sept. 30, 2008 1.171B
June 30, 2008 1.169B
March 31, 2008 1.078B
Dec. 31, 2007 1.382B
Sept. 30, 2007 1.440B
June 30, 2007 1.030B
March 31, 2007 1.03B
Dec. 31, 2006 1.723B
Sept. 30, 2006 945.40M
June 30, 2006 1.172B
March 31, 2006 942.00M
Dec. 31, 2005 1.112B
Sept. 30, 2005 942.60M
June 30, 2005 946.80M
March 31, 2005 846.60M
Dec. 31, 2004 1.109B
Sept. 30, 2004 919.30M
June 30, 2004 986.00M
March 31, 2004 996.30M
Dec. 31, 2003 906.30M
Sept. 30, 2003 776.50M
June 30, 2003 786.40M
March 31, 2003 810.70M
Dec. 31, 2002 838.80M

There is no data for the selected date range.

An error occurred. Please try again by refreshing your browser or contact us with details of your problem.

About R&D Expense

R&D expenses are a line item from many companies' income statements.

R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More


MRK Research and Development Expense (Quarterly) Benchmarks

AstraZeneca 1.356B
Bristol-Myers Squibb 1.016B
GlaxoSmithKline 1.315B

MRK Research and Development Expense (Quarterly) Range, Past 5 Years

Minimum 1.574B Mar 2014
Maximum 4.559B Dec 2010
Average 2.102B

MRK Research and Development Expense (Quarterly) Excel Add-In Codes

  • Metric Code: r_and_d_expense
  • Latest data point: =YCP("MRK", "r_and_d_expense")
  • Last 5 data points: =YCS("MRK", "r_and_d_expense", -4)

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.


You've hit the 10 page limit on YCharts.

Experience the power of YCharts.
Start your Free 7-Day Trial.

Start My Free Trial No credit card required.

Already a subscriber? Sign in.


Start your free 7-Day Trial.

{{}} No credit card required.

Already a subscriber? Sign in.